VERV Profile
Verve Therapeutics, Inc. is a pioneering genetic medicines company focused on developing innovative gene editing therapies for cardiovascular diseases. The company’s lead product candidate, VERVE-101, is a groundbreaking single-course treatment designed to permanently inactivate the PCSK9 gene in the liver. PCSK9 is a key regulator of cholesterol levels, and its inhibition is expected to have a significant impact on lowering LDL cholesterol, thereby reducing the risk of heart disease.
In addition to VERVE-101, Verve Therapeutics is advancing its ANGPTL3 program, which aims to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is another important gene involved in lipid metabolism, and its inhibition could further enhance cardiovascular health by modifying lipid levels and reducing cardiovascular disease risk.
Verve Therapeutics has established several strategic collaborations to advance its gene editing technologies. The company has a collaboration and license agreement with Beam Therapeutics Inc., focusing on developing next-generation gene editing tools. It also has a development and option agreement with Acuitas Therapeutics, Inc. for the delivery of genetic medicines, and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College, providing access to essential gene editing technology.
Founded in 2018 as Endcadia, Inc., Verve Therapeutics rebranded to its current name in January 2019 to better reflect its focus on transformative genetic therapies. Headquartered in Cambridge, Massachusetts, the company is at the forefront of gene editing innovation, leveraging cutting-edge technologies to develop treatments that address the root causes of cardiovascular diseases and potentially other genetic conditions. Its strategic partnerships and robust pipeline underscore its commitment to advancing genetic medicine for improved patient outcomes.
|
